Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
 
COORDINADOR

Coordinador: Dr. Luis Montuenga Badia
Centro: Centro para la Investigación Médica Aplicada
Dirección postal: Avda. Pío XII, 55, 31008, Pamplona
Email: lmontuenga[arroba]unav.es

Breve CV: Dr. Luis M. Montuenga got his undergraduate degree with Honors in Biology from the University of Navarra (Spain). He also has a Master of Sciences (MSc) in Neuroendocrine Cell Biology from University College London (UK). In 1984 got his Ph.D. in Biology from the University of Navarra (Spain). He spent two years as postgraduate fellow at the Royal Postgraduate Medical School in London and was Visiting Scientist at the National Cancer Institute (NIH) in Bethesda (Maryland) during three years (1995-1998). He is currently Full Professor of Cell Biology at the School of Medicine of the University of Navarra and Senior Researcher and Head of the Oncology Division of the Center for Applied Medical Research (CIMA), University of Navarra. In the past Dr. Montuenga has been the Head of the Histology and Pathology Department of the School of Medicine (1998-2007) and Vicepresident of Research of the University of Navarra (2008-2011). 

Dr. Montuenga has authored more than 120 peer-reviewed publications in Cell Biology and Oncology, has directed 18 doctoral theses and has given numerous conferences and seminars internationally. His research activity is primarily focused on lung cancer. At the Center of Applied Medical Research he co-leads, together with Dr. Ruben Pio, the Laboratory of Lung Cancer Biomarkers. The laboratory of Biomarker’s is focused on the molecular mechanisms associated with the transformation of normal lung epithelial cells into lung tumors. One of its main translational aims is to find molecular markers related to lung carcinogenesis to develop new strategies for lung cancer early detection. Other research interest of the group is to design new molecular targeted therapies that may be useful in the treatment of lung tumors.

He has served as ad hoc reviewer in a variety of national and international research evaluation agencies and has been involved in the peer review process of a large number of journals of his research field.  He is currently Associate Editor of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

He is founding member of the European Union Early Lung Cancer (EUELC), member of the prevention Committee of the IASLC, Active member of the American Association for Cancer Research (AACR) and the European Respiratory Society as well as Spanish scientific research societies like the Asociación Española de Investigación en Cáncer (ASEICA) or the Spanish Society for Cell Biology (SEBC).

In the past editions of the RTICC network, Dr. Montuenga has been the Coordinator for Training and Mobility and now serves as Coordinator of the Respiratory Tract Tumors Program.

Introducción
Coordinador
Grupos
Work Packages
Publicaciones
Proyectos
Ensayos clínicos
Otros resultados
Agenda
Enlaces
Intranet
Noticias
Publicaciones
RD12/0036/0056
Correction: HPV Testing by cobas HPV Test in a Population from Catalonia.
Lloveras B, Gomez S, Alameda F, Bellosillo B, Mojal S, Muset M, Parra M, Palomares JC, Serrano S
PLoS One  2013.  10.  PMID: 24204493. 

RD12/0036/0018
Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4.
Leenders M, Bhattacharjee S, Vineis P, Stevens V, Bueno-de-Mesquita HB, Shu XO, Amundadottir L, Gross M, Tobias GS, Wactawski-Wende J, Arslan AA, Duell EJ, Fuchs CS, Gallinger S, Hartge P, Hoover RN, Holly EA, Jacobs EJ, Klein AP, Kooperberg C, LaCroix A, Li D, Mandelson MT, Olson SH, Petersen G, Risch HA, Yu K, Wolpin BM, Zheng W, Agalliu I, Albanes D, Boutron-Ruault MC, Bracci PM, Buring JE, Canzian F, Chang K, Chanock SJ, Cotterchio M, Gaziano JM, Giovanucci EL, Goggins M, Hallmans G, Hankinson SE, Hoffman-Bolton JA, Hunter DJ, Hutchinson A, Jacobs KB, Jenab M, Khaw KT, Kraft P, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Patel AV, Rabe KG, Riboli E, Tjønneland A, Trichopoulos D, Virtamo J, Visvanathan K, Elena JW, Yu H, Zeleniuch-Jacquotte A, Stolzenberg-Solomon RZ
Cancer Causes Control  2013.  3.  595-602.  PMID: 23334854. 

RD12/0036/0056
Human papillomavirus detection and p16(INK4a) expression in cervical lesions: a comparative study.
Genovés J, Alameda F, Mancebo G, Solé JM, Bellosillo B, Lloveras B, Agramunt S, Baró MT, Muset M, Casado B, Serrano L, Miralpeix E, Carreras R
Hum Pathol  2014.  4.  826-33.  PMID: 24656093. 

RD12/0036/0056
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR, de la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A, Gotel (Spanish Lymphoma Oncology Group)
Leuk Lymphoma  2014.  1.  51-5.  PMID: 23573825. 

RD12/0036/0018
Intake of coffee, decaffeinated coffee, or tea does not affect risk for pancreatic cancer: results from the European Prospective Investigation into Nutrition and Cancer Study
51. Bhoo-Pathy N, Uiterwaal CS, Dik VK, Jeurnink SM, Bech BH, Overvad K, Halkjær J, Tjønneland A, Boutron-Ruault MC, Fagherazzi G, Racine A, Katzke VA, Li K, Boeing H, Floegel A, Androulidaki A, Bamia C, Trichopoulou A, Masala G, Panico S, Crosignani P, Tumino R, Vineis P, Peeters PH, Gavrilyuk O, Skeie G, Weiderpass E, Duell EJ, Arguelles M, Molina-Montes E, Navarro C, Ardanaz E, Dorronsoro M, Lindkvist B, Wallström P, Sund M, Ye W, Khaw KT, Wareham N, Key TJ, Travis RC, Duarte-Salles T, Freisling H, Licaj I, Gallo V, Michaud DS, Riboli E, Bueno-De-Mesquita HB.
Clin Gastroenterol Hepatol  2013.  11.  1486-92.  PMID: 23756220 . 

RD12/0036/0018
Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study.
Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR
J Invest Dermatol  2013.  8.  1950-5.  PMID: 23344461. 

RD12/0036/0056
Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.
Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, Capocaccia R, Giacomin A, Lutz JM, Martos C, Sankila R, Johannesen TB, Simonetti A, Sant M, HAEMACARE Working Group
Haematologica  2013.  2.  230-8.  PMID: 22983589. 

RD12/0036/0056
Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002.
Gatta G, Rossi S, Foschi R, Trama A, Marcos-Gragera R, Pastore G, Peris-Bonet R, Stiller C, Capocaccia R, EUROCARE Working Group
Haematologica  2013.  5.  744-52.  PMID: 23403323. 

RD12/0036/0056
Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project.
van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T, RARECARE WG
Eur J Cancer  2013.  11.  2565-78.  PMID: 23541566. 

RD12/0036/0056
Cancer prevalence estimates in Europe at the beginning of 2000.
Gatta G, Mallone S, van der Zwan JM, Trama A, Siesling S, Capocaccia R, EUROCARE Working Group
Ann Oncol  2013.  6.  1660-6.  PMID: 23553062. 

ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
 
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
 
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS